OncoMatch/Clinical Trials/NCT07085572
Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer
Is NCT07085572 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cemiplimab for adrenal cortical carcinoma.
Treatment: Cemiplimab — This clinical trial is a single-arm, non-randomized, prospective phase II study. The study aims to evaluate if the maintenance immunotherapy with cemiplimab in patients with AdrenoCortical Carcinoma (ACC), who obtained disease response or stabilization after first-line chemotherapy, may delay/prevent disease progression. The study will be conducted at ASST Spedali Civili Hospital, Brescia - Italy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EDP-M induction therapy — first line
Previous induction therapy with EDP-M followed by cytoreductive surgery if indicated
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor
Cannot have received: allogeneic stem cell transplantation
Prior allogeneic stem cell transplantation
Cannot have received: autologous stem cell transplantation
autologous stem cell transplantation
Lab requirements
Blood counts
Hemoglobin >9.0 g/dL; ANC >1.5 x 10^9/L; Platelet count >75 x 10^9/L
Kidney function
Serum creatinine <1.5 ULN or estimated CrCl >30 mL/min
Liver function
Total bilirubin <1.5 x ULN; AST and ALT both <3 x ULN; ALP <2.5 x ULN; For patients with Gilbert's syndrome, total bilirubin ≤3x ULN
Adequate organ and bone marrow function documented by: Hemoglobin >9.0 g/dL; ANC >1.5 x 10^9/L; Platelet count >75 x 10^9/L; Serum creatinine <1.5 ULN or estimated CrCl >30 mL/min; Adequate hepatic function: Total bilirubin <1.5 x ULN; AST and ALT both <3 x ULN; ALP <2.5 x ULN; For patients with Gilbert's syndrome, total bilirubin ≤3x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify